Showing 21 - 30 of 38,814
Persistent link: https://www.econbiz.de/10005449048
Background: Direct-to-consumer advertising (DTCA) is legal in the US and New Zealand, but illegal in the rest of the world. Little or no research exists on the social welfare implications of DTCA. Aim: To quantify the total costs and benefits associated with both appropriate and inappropriate...
Persistent link: https://www.econbiz.de/10005449192
Persistent link: https://www.econbiz.de/10005449213
Objective: Invasive disease caused by Haemophilus influenzae type b (Hib), including meningitis, pneumonia, sepsis and epiglottitis, is associated with high mortality and serious neurological sequelae in children under 5 years of age. The availability of an efficacious vaccine suggests the need...
Persistent link: https://www.econbiz.de/10005449321
The objective of this review was to identify health-related workplace productivity loss survey instruments, with particular emphasis on those that capture a metric suitable for direct translation into a monetary figure. A literature search using Medline, HealthSTAR, PsycINFO and Econlit...
Persistent link: https://www.econbiz.de/10005404872
Objective: To develop and apply a model to assess the economic value of a workplace influenza programme from the perspective of the employer. Design: The model calculated the avoided costs of influenza, including treatment costs, lost productivity, lost worker added value and the cost of...
Persistent link: https://www.econbiz.de/10005404933
Opiate dependence imposes a significant economic burden on society in terms of treatment-related costs and prevention services, other healthcare costs, the work absenteeism of patients, productivity loss arising from premature death of patients, costs associated with crime, and social welfare...
Persistent link: https://www.econbiz.de/10005404977
In this study, the benefits and costs of treating schizophrenia with either risperidone or clozapine were examined. The lifetime drug-treatment cost incurred by a patient with schizophrenia in Israel was $US7561 (1996 values) with an initial 6-month trial with risperidone, compared with $US6326...
Persistent link: https://www.econbiz.de/10005590320
Uncertainty in the decision-making process for reimbursement of health technologies could be reduced if additional information were available. Although methods to evaluate the monetary value of the uncertainty have been previously described, an economic evaluation of alternative methods to...
Persistent link: https://www.econbiz.de/10005590472
The availability of new atypical antipsychotics, such as risperidone, that have higher acquisition costs than conventional treatments has prompted pharmacoeconomic evaluation of their costs and benefits. Risperidone is reported to have superior efficacy to haloperidol and similar efficacy to...
Persistent link: https://www.econbiz.de/10005590536